-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $48

Benzinga·05/15/2025 14:58:02
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform and raises the price target from $44 to $48.